Antibiotic trapping by plasmid-encoded cmy-2-lactamase combined with reduced outer membrane permeability as a mechanism of carbapenem resistance in escherichia coli

Antimicrobial Agents and Chemotherapy

Volumn 57, Issue 8, 2013, Pages 3941-3949

  Goessens, Wil H F ^a   Van Der Bij, Akke K ^a,f,g   Van Boxtel, Ria ^b   Pitout, Johann D D ^c,d   Van Ulsen, Peter ^e   Melles, Damian C ^a   Tommassen, Jan ^b  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b UTRECHT UNIVERSITY   (Netherlands)

^c CALGARY LABORATORY SERVICES   (Canada)

^d UNIVERSITY OF CALGARY   (Canada)

^e VU UNIVERSITY AMSTERDAM   (Netherlands)

^f NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

^g REINIER DE GRAAF HOSPITAL   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BETA LACTAMASE CTX M; CARBAPENEM; MEROPENEM; NITROCEFIN; OUTER MEMBRANE PROTEIN C; OUTER MEMBRANE PROTEIN F;

ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL OUTER MEMBRANE; BACTERIUM CULTURE; BACTERIUM DETECTION; BACTERIUM ISOLATION; CARBAPENEM RESISTANT ESCHERICHIA COLI; CARBAPENEM SUSCEPTIBLE ESCHERICHIA COLI; CHOLANGITIS; CONTROLLED STUDY; DRUG HYDROLYSIS; ELECTROPHORETIC MOBILITY; ENZYME ACTIVITY; ESCHERICHIA COLI; HOSPITAL ADMISSION; IN VITRO STUDY; IN VIVO STUDY; MASS SPECTROMETRY; MEMBRANE PERMEABILITY; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; SEQUENCE ANALYSIS;

ANTI-BACTERIAL AGENTS; BACTERIAL OUTER MEMBRANE PROTEINS; BETA-LACTAMASES; CELL MEMBRANE PERMEABILITY; CEPHALOSPORINS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; ENZYME ACTIVATION; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTIONS; ESCHERICHIA COLI PROTEINS; FEMALE; HUMANS; HYDROLYSIS; MICROBIAL SENSITIVITY TESTS; PERIPLASM; PLASMIDS; PROTEIN BINDING; THIENAMYCINS; YOUNG ADULT;

EID: 84880284447     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.02459-12     Document Type: Article

References (53)

1. Nordmann P, Cuzon G, Naas T. 2009. The real threat of Klebsiella pneumoniae carbapenemase-producing bacteria. Lancet Infect. Dis. 9:228-236.
2. Walsh TR, Toleman MA, Poirel L, Nordmann P. 2005. Metallo-lactamases: the quiet before the storm?. Clin. Microbiol. Rev. 18:306-325.
3. Doumith M, Ellington MJ, Livermore DM, Woodford N. 2009. Molecular mechanisms disrupting porin expression in ertapenem-resistant Klebsiella and Enterobacter spp. clinical isolates from the UK. J. Antimicrob. Chemother. 63:659-667.
4. Liu Y-F, Yan JJ, Ko WC, Tsai SH, Wu JJ. 2008. Characterization of carbapenem-non-susceptible Escherichia coli isolates from a university hospital in Taiwan. J. Antimicrob. Chemother. 61:1020-1023.
5. Yang Q, Wang H, Sun H, Chen H, Xu Y, Chen M. 2010. Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China. Antimicrob. Agents Chemother. 54:573-577.
6. Mammeri H, Guillon H, Eb F, Nordmann P. 2010. Phenotypic and biochemical comparison of the carbapenem-hydrolyzing activities of five plasmid-borne AmpC-lactamases. Antimicrob. Agents Chemother. 54: 4556-4560.
7. Queenan AM, Shang W, Flamm R, Bush K. 2010. Hydrolysis and inhibition profiles of-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem. Antimicrob. Agents Chemother. 54:565-569.
8. Lakaye B, Dubus A, Lepage S, Groslambert S, Frére JM. 1999. When drug inactivation renders the target irrelevant to antibiotic resistance: a case story with-lactams. Mol. Microbiol. 31:89-101.
9. Gutmann L, Williamson R. 1983. A model system to demonstrate that-lactamase-associated antibiotic trapping could be a potential means of resistance. J. Infect. Dis. 148:316-321.
10. Livermore DM. 1985. Do-lactamases 'trap' cephalosporins?. J. Antimicrob. Chemother. 15:511-514.
11. Sanders CC. 1984. Inducible-lactamases and non-hydrolytic resistance mechanisms. J. Antimicrob. Chemother. 13:1-3.
12. Then RL, Angehrn P. 1982. Trapping of nonhydrolyzable cephalosporins by cephalosporinases in Enterobacter cloacae and Pseudomonas aeruginosa as a possible resistance mechanism. Antimicrob. Agents Chemother. 21: 711-717.
13. Livermore DM. 1987. Covalent trapping and latamoxef resistance in-lactamase-derepressed Pseudomonas aeruginosa. J. Antimicrob. Chemother. 20:7-13.
14. Vu H, Nikaido H. 1985. Role of-lactam hydrolysis in the mechanism of resistance of a-lactamase-constitutive Enterobacter cloacae strain to expanded-spectrum-lactams. Antimicrob. Agents Chemother. 27:393-398.
15. Antunes NT, Frase H, Toth M, Mobashery S, Vakulenko SB. 2011. Resistance to third-generation cephalosporin ceftazidime by a deacylation-deficient mutant of the TEM-lactamase by the uncommon covalent-trapping mechanism. Biochemistry 50:6387-6395.
16. Beadle BM, Shoichet BK. 2002. Structural basis for imipenem inhibition of class C-lactamases. Antimicrob. Agents Chemother. 46:3978-3980.
17. Clinical and Laboratory Standards Institute. 2010. Performance standards for antimicrobial susceptibility testing. 20th informational supplement. Clinical and Laboratory Standards Institute, Wayne, PA.
18. Pitout JDD, Gregson DB, Campbell L, Laupland KB. 2009. Molecular characteristics of extended-spectrum-lactamase-producing Escherichia coli isolates causing bacteremia in the Calgary Health Region from 2000 to 2007: emergence of clone ST131 as a cause of community-acquired infections. Antimicrob. Agents Chemother. 53:2846-2851.
19. Tenover FC, Arbeit RD, Goering RV, Mickelsen PA, Murray BE, Persing DH, Swaminathan B. 1995. Interpreting chromosomal DNA restriction patterns produced by pulsed-field gel electrophoresis: criteria for bacterial strain typing. J. Clin. Microbiol. 33:2233-2239.
20. Levinthal C, Singer ER, Fetherolf K. 1962. Reactivation and hybridization of reduced alkaline phosphatase. Proc. Natl. Acad. Sci. U. S. A. 48: 1230-1237.
21. Tommassen J, van Tol H, Lugtenberg B. 1983. The ultimate localization of an outer membrane protein of Escherichia coli K-12 is not determined by the signal sequence. EMBO J. 2:1275-1279.
22. Lugtenberg B, Meijers J, Peters R, van der Hoek P, van Alphen L. 1975. Electrophoretic resolution of the major outer membrane protein of Escherichia coli K-12 into four bands. FEBS Lett. 58:254-258.
23. Laemmli UK. 1970. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227:680-685.
24. Hasman H, Mevius D, Veldman K, Olesen I, Aarestrup FM. 2005.-Lactamases among extended-spectrum-lactamase (ESBL)-resistant Salmonella from poultry, poultry products and human patients in The Netherlands. J. Antimicrob. Chemother. 56:115-121.
25. Karisik E, Ellington MJ, Pike R, Warren RE, Livermore DM, Woodford N. 2006. Molecular characterization of plasmids encoding CTX-M-15-lactamases from Escherichia coli strains in the United Kingdom. J. Antimicrob. Chemother. 58:665-668.
26. Mabilat C, Goussard S. 1993. PCR detection and identification of genes for extended-spectrum-lactamases, p 553-559. In Persing DH, Smith TF, Tenover FC, White TJ (ed), Diagnostic molecular microbiology: principles and applications. American Society for Microbiology, Washington, DC.
27. Pérez-Pérez FJ, Hanson ND. 2002. Detection of plasmid-mediated AmpC-lactamase genes in clinical isolates by using multiplex PCR. J. Clin. Microbiol. 40:2153-2162.
28. Severin JA, Mertaniasih NM, Kuntaman K, Lestari ES, Purwanta M, Lemmens-Den Toom N, Duerink DO, Hadi U, van Belkum A, Verbrugh HA, Goessens WH, Study Group Antimicrobial Resistance in Indonesia: Prevalence and Prevention (AMRIN). 2010. Molecular characterization of extended-spectrum-lactamases in clinical Escherichia coli and Klebsiella pneumoniae isolates from Surabaya, Indonesia. J. Antimicrob. Chemother. 65:465-469.
29. Woodford N, Fagan EJ, Ellington MJ. 2006. Multiplex PCR for rapid detection of genes encoding CTX-M extended-spectrum-lactamases. J. Antimicrob. Chemother. 57:154-155.
30. Bradford PA, Bratu S, Urban C, Visalli M, Mariano N, Landman D, Rahal JJ, Brooks S, Cebular S, Quale J. 2004. Emergence of carbapenemresistant Klebsiella species possessing the class A carbapenem-hydrolyzing KPC-2 and inhibitor-resistant TEM-30-lactamases in New York City. Clin. Infect. Dis. 39:55-60.
31. Pitout JDD, Gregson DB, Poirel L, McClure JA, Le P, Church DL. 2005. Detection of Pseudomonas aeruginosa producing metallo-lactamases in a large centralized laboratory. J. Clin. Microbiol. 43:3129-3135.
32. Bauernfeind A, Stemplinger I, Ungwirth R, Giamarellou H. 1996. Characterization of the plasmidic-lactamase CMY-2, which is responsible for cephamycin resistance. Antimicrob. Agents Chemother. 40:221-224.
33. Renault M, Tommassen-van Boxtel R, Bos MP, Post JA, Tommassen J, Baldus M. 2012. Cellular solid-state nuclear magnetic resonance spectroscopy. Proc. Natl. Acad. Sci. U. S. A. 109:4863-4868.
34. O'Callaghan CH, Morris A, Kirby SM, Shingler AH. 1972. Novel method for detection of-lactamases by using a chromogenic cephalosporin substrate. Antimicrob. Agents Chemother. 1:283-288.
35. Osborn MJ, Gander JE, Parisi E. 1972. Mechanism of assembly of the outer membrane of Salmonella typhimurium. Site of synthesis of lipopolysaccharide. J. Biol. Chem. 247:3973-3986.
36. Zimmermann W, Rosselet A. 1977. Function of the outer membrane of Escherichia coli as a permeability barrier to beta-lactam antibiotics. Antimicrob. Agents Chemother. 12:368-372.
37. Voulhoux R, Bos MP, Geurtsen J, Mols M, Tommassen J. 2003. Role of a highly conserved bacterial protein in outer membrane protein assembly. Science 299:262-265.
38. Roussel-Jazédé V, Jongerius I, Bos MP, Tommassen J, van Ulsen P. 2010. NalP-mediated proteolytic release of lactoferrin-binding protein B from the meningococcal cell surface. Infect. Immun. 78:3083-3089.
39. Martínez-Martínez L, Pascual A, Hernández- Allés S, Alvarez-Díaz D, Suárez I, Tran J, Bendí VJ, Jacoby GA. 1999. Roles of-lactamases and porins in activities of carbapenems and cephalosporins against Klebsiella pneumoniae. Antimicrob. Agents Chemother. 43:1669-1673.
40. Poirel L, Héritier C, Spicq C, Nordmann P. 2004. In vivo acquisition of high-level resistance to imipenem in Escherichia coli. J. Clin. Microbiol. 42:3831-3833.
41. Nikaido H. 2003. Molecular basis of bacterial outer membrane permeability revisited. Microbiol. Mol. Biol. Rev. 67:593-656.
42. Janssen R, Verjans GM, Kusters JG, Tommassen J. 1995. Induction of the phoE promoter upon invasion of Salmonella typhimurium into eukaryotic cells. Microb. Pathog. 19:193-201.
43. Tommassen J, Lugtenberg B. 1980. Outer membrane protein e of Escherichia coli K-12 is co-regulated with alkaline phosphatase. J. Bacteriol. 143:151-157.
44. Mata C, Miró E, Rivera A, Mirelis B, Coll P, Navarro F. 2010. Prevalence of acquired AmpC-lactamases in Enterobacteriaceae lacking inducible chromosomal ampC genes at a Spanish hospital from 1999 to 2007. Clin. Microbiol. Infect. 16:472-476.
45. Naseer U, Haldorsen B, Simonsen GS, Sundsfjord A. 2010. Sporadic occurrence of CMY-2-producing multidrug-resistant Escherichia coli of ST-complexes 38 and 448, and ST131 in Norway. Clin. Microbiol. Infect. 16:171-178.
46. Woodford N, Reddy S, Fagan EJ, Hill RL, Hopkins KL, Kaufmann ME. 2007. Wide geographic spread of diverse acquired AmpC-type-lactamases among Escherichia coli and Klebsiella spp. in the UK and Ireland. J. Antimicrob. Chemother. 59:102-105.
47. Baudry PJ, Mataseje L, Zhanel GG, Hoban DJ, Mulvey MR. 2009. Characterization of plasmids encoding CMY-2 AmpC-lactamases from Escherichia coli in Canadian intensive care units. Diagn. Microbiol. Infect. Dis. 65:379-383.
48. Pitout JDD, Le PG, Moore KL, Church DL, Gregson DB. 2010. Detection of AmpC-lactamases in Escherichia coli, Klebsiella spp., Salmonella spp., and Proteus mirabilis in a regional clinical microbiology laboratory. Clin. Microbiol. Infect. 16:165-170.
49. Hanson ND, Moland ES, Hong SG, Propst K, Novak DJ, Cavalieri SJ. 2008. Surveillance of community-based reservoirs reveals the presence of CTX-M, imported AmpC, and OXA-30-lactamases in urine isolates of Klebsiella pneumoniae and Escherichia coli in a U.S. community. Antimicrob. Agents Chemother. 52:3814-3816.
50. Pitout JDD, Gregson DB, Church DL, Laupland KB. 2007. Populationbased laboratory surveillance for AmpC-lactamase-producing Escherichia coli, Calgary. Emerg. Infect. Dis. 13:443-448.
51. Nikaido H. 1994. Prevention of drug access to bacterial targets: permeability barriers and active efflux. Science 264:382-388.
52. Pechère JC, Levesque R. 1983.-lactamases: clinical and genetic perspectives. J. Antimicrob. Chemother. 12:529-534.
53. Hugonnet JE, Tremblay LW, Boshoff HI, Barry CE, III, Blanchard JS. 2009. Meropenem-clavulanate is effective against extensively drugresistant Mycobacterium tuberculosis. Science 323:1215-1219.